Various effects of antipsychotics on p50 sensory gating in Chinese schizophrenia patients: A meta-analysis

Psychiatria Danubina

Volumn 24, Issue 1, 2012, Pages 44-50

  Su, Liang ^a   Cai, Yiyun ^a   Wang, Liwei ^a   Shi, Shenxun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antipsychotics; Meta analysis; P50; Schizophrenia; Sensory gating

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE;

ARTICLE; CHINA; CHINESE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; SCHIZOPHRENIA; SENSORY GATING; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN; EVOKED POTENTIALS, AUDITORY; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING;

EID: 84860804983     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT et al.: Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 2004; 161: 1822-8. (Pubitemid 39314676)
2. Arango C, Summerfelt A, Buchanan RW: Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry 2003; 160: 2066-8. (Pubitemid 39619651)
3. Becker J, Gomes I, Ghisolfi ES, Schuch A, Ramos FL, Ehlers JA et al.: Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol 2004; 115: 396-401. (Pubitemid 38117261)
4. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S: Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004; 70: 315-29. (Pubitemid 39141109)
5. Carroll CA, O'Donnell BF, Shekhar A, Hetrick WP: The effects of olanzapine on sensory gating in healthy participants. Schizophr Res 2004; 66:187-9. (Pubitemid 38041119)
6. Chen R, Copeland JR, Wei L: A meta-analysis of epidemiological studies in depression of older people in the People's Republic of China. Int J Geriatr Psychiatry 1999; 14:821-30. (Pubitemid 29495543)
7. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX: Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 2008; 33:497-512.
8. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH: A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res 2007; 97:137-51.
9. Liu DT, Zhuo KM, Song ZH, Wu Y, Chen XS, Wang JJ et al.: Effect of risperidone on sensory gating P50 deficit in patients with schizophrenia. Journal of Shanghai Jiaotong University Medical Science 2010; 30:1525-8.
10. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997a; 315:629-34. (Pubitemid 27387172)
11. Egger M, Smith GD, Phillips AN: Meta-analysis: principles and procedures. BMJ 1997b; 315:1533-7. (Pubitemid 27517188)
12. Fuerst DR, Gallinat J, Boutros NN: Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 2007; 44:620-6. (Pubitemid 46905321)
13. Yang GG, Tan YL, Yang FD, Li J, Chen S, Zhang JG et al.: Effects of risperidone on auditory gating potential P50 in acute medication-free patients with schizophrenia. Chinese Mental Health Journal 2010; 24:265-8.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60. (Pubitemid 37088507)
15. Hong X, Chan RC, Zhuang X, Jiang T, Wan X, Wang J et al.: Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res 2009; 108:151-7.
16. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5:13.
17. Hunter JE, Schmidt FL: Methods of meta-analysis: Correcting error and bias in research findings: Sage Publications, Inc 2004.
18. Wang JJ, Li CB, Zhu ZQ, Chen XS, Li H, Huang LP et al.: The influence of duration of unmedicated psychosis on the neurocognitive functions of drug- naive and first episode schizophrenia. Shanghai Archives of Psychiatry 2008; 20: 261-4.
19. Lewis S, Clarke M: Forest plots: trying to see the wood and the trees. BMJ 2001; 322: 1479-80. (Pubitemid 32575420)
20. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL: Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000; 157:767-71. (Pubitemid 30249656)
21. Mann C, Croft RJ, Scholes KE, Dunne A, O'Neill BV, Leung S et al.: Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and P50 suppression measures of sensorimotor and sensory gating in humans. Neuropsychopharmacology 2008; 33:1653-66. (Pubitemid 351684715)
22. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996; 40:181-8. (Pubitemid 26349110)
23. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G et al.: Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999; 39:10-7. (Pubitemid 29037759)
24. Naylor CD: Meta-analysis and the meta-epidemiology of clinical research. BMJ 1997; 315: 617-9.
25. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H et al.: P50 sensory gating ratios in schizophrenics and controls: A review and data analysis. Psychiat Res 2008; 158: 226-47.
26. Potter D, Summerfelt A, Gold J, Buchanan R: Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophren Bull 2006; 32:692-700. (Pubitemid 44412856)
27. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT: Neurobiology of schizophrenia. Neuron 2006; 52:139-53. (Pubitemid 44466356)
28. Sanchez-Morla EM, Santos JL, Aparicio A, Garcia- Jimenez MA, Villanueva C, Martinez-Vizcaino V et al.: Antipsychotic effects on auditory sensory gating in schizophrenia patients. Eur Neuropsychopharmacol 2009; 19:905-9.
29. Su L, Hu H, Chen J, Wang JJ, Wang L, Shi SX: P50 sensory gating studies in schizophrenics: a systematic review. Zhonghua Yi Xue Za Zhi 2010; 90:2020-5.
30. Su L, Hu H, Shi S, Li H, Wang L, Wang J: Comparison of the effects of clozapine and chlorpromazine on auditory sensory gating in patients with schizophrenia: a prospective case-control study. Shanghai Archives of Psychiatry 2011; 23:12-6.
31. Turetsky B, Calkins M, Light G, Olincy A, Radant A, Swerdlow N: Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophren Bull 2007; 33:69-94. (Pubitemid 46026260)
32. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60.
33. Wang J: Evidence-based medicine in China. Lancet 2010; 375:532-3.
34. Wolf FM: Meta-analysis: Quantitative methods for research synthesis 1986.
35. Chen XS, Zhang MD, Lou FY, Wang HX, Wang JJ, Guo Q et al: Follow-up study on sensory gating in first-episode schizophrenia. Chin J Psychiatry 2006; 39:193-6.
36. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. Journal of Abnormal Psychology 1998; 107:691-8. (Pubitemid 28527584)